Equities
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Gilead Sciences, Inc. is a biopharmaceutical company that is focused on advancing medicines to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company's portfolio of products and pipeline of investigational drugs includes treatments for HIV/acquired immune deficiency syndrome (AIDS), COVID-19, liver diseases, hematology/oncology/cell therapy and other. Its products for HIV/AIDS patients include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada and Atripla. It offers Veklury to patients with COVID-19. The Company's products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Viread and Vosevi. Its products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy and Zydelig. Other products include Letairis, Ranexa and AmBisome. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. The Company operates in more than 335 countries worldwide.

  • Revenue in USD (TTM)26.64bn
  • Net income in USD5.16bn
  • Incorporated1987
  • Employees13.60k
  • Location
    Gilead Sciences Inc333 LAKESIDE DRFOSTER CITY 94404United StatesUSA
  • Phone+1 (650) 574-3000
  • Fax+1 (650) 578-9264
  • Websitehttps://www.gilead.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
GILD:NSQ since
announced
Transaction
value
MYR GmbHDeal completed10 Dec 202010 Dec 2020Deal completed10.00%1.75bn
Data delayed at least 15 minutes, as of Oct 19 2021 21:00 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Vertex Pharmaceuticals Incorporated6.68bn1.99bn46.90bn3.40k23.835.0922.257.027.597.5925.5035.490.59582.997.771,965,814.0017.7515.7221.1819.5687.8987.6629.8025.124.4365.360.0540.0049.0743.15130.42--41.81--
Iqvia Holdings Inc12.93bn607.00m47.61bn74.00k79.818.2624.393.683.113.1166.3130.060.5489--5.57184,728.602.641.143.261.3733.5933.994.822.39--2.920.68080.002.4414.6446.07-6.3451.03--
Regeneron Pharmaceuticals Inc12.38bn6.21bn58.13bn9.12k9.763.838.994.6955.7155.71110.75141.750.68961.262.521,357,459.0034.5619.4343.5822.6786.8591.0350.1130.843.19--0.1513--8.0615.6766.0540.75-1.94--
Gilead Sciences, Inc.26.64bn5.16bn82.63bn13.60k16.174.1911.763.104.074.0721.0415.710.42993.757.261,958,677.008.2911.059.9713.3080.1481.9219.2827.471.193.100.604943.079.98-5.43-97.72-63.15-2.7416.09
Zoetis Inc7.41bn1.91bn96.08bn11.30k50.7622.1040.8312.963.993.9915.509.170.54631.336.88655,929.2014.0512.9916.4115.2469.6767.8725.7222.132.5110.710.623121.886.636.979.2037.0315.1319.23
Amgen, Inc.25.48bn5.75bn115.35bn24.30k20.6514.0312.524.539.849.8443.7514.480.40851.585.181,048,724.009.2111.2011.5313.3675.3480.7022.5533.201.039.700.79944.508.833.25-7.370.91970.46715.16
Data as of Oct 19 2021. Currency figures normalised to Gilead Sciences Inc's reporting currency: US Dollar USD

Institutional shareholders

40.75%Per cent of shares held by top holders
HolderShares% Held
Capital Research & Management Co. (Global Investors)as of 30 Jun 2021116.67m9.31%
The Vanguard Group, Inc.as of 30 Jun 202199.72m7.95%
BlackRock Fund Advisorsas of 30 Jun 202177.78m6.20%
SSgA Funds Management, Inc.as of 30 Jun 202154.30m4.33%
Capital Research & Management Co. (International Investors)as of 30 Jun 202139.44m3.15%
Capital Research & Management Co. (World Investors)as of 30 Jun 202135.99m2.87%
Dodge & Coxas of 30 Jun 202128.96m2.31%
Geode Capital Management LLCas of 30 Jun 202121.92m1.75%
Capital Research & Management Co.as of 31 Jul 202119.79m1.58%
BlackRock Investment Management (UK) Ltd.as of 30 Jun 202116.41m1.31%
More ▼
Data from 30 Jun 2021 - 31 Jul 2021Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
image